Rhea-AI Summary
Vivoryon Therapeutics N.V. announced that Dr. Ulrich Dauer, the CEO, will present at the 2023 BIO CEO & Investor Conference in New York City on February 6 at 10:15 am EST. The conference, scheduled from February 6-9, 2023, will feature insights into the company’s innovative approach to treating Alzheimer’s disease through its oral small molecule QPCT/L inhibitor, varoglutamstat, currently in Phase 2 development. Vivoryon focuses on developing small molecule medicines targeting altered proteins in various diseases, including cancer and inflammatory conditions. The presentation is for registered attendees only.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags